Literature DB >> 2651204

Effects of cyclosporin A on active Crohn's disease.

T Fukushima1, A Sugita, S Masuzawa, Y Yamazaki, S Tsuchiya.   

Abstract

Seven patients with active Crohn's disease were treated with cyclosporin A orally for 16 weeks. The initial dose was 8 mg/kg/day and the subsequent dose was adjusted to maintain the plasma concentration of cyclosporin A of approximately 200 ng/ml. The mean value of the Crohn's disease activity index before treatment was 194.3 +/- 57.4. It was gradually decreased reaching a nadir at 12 weeks (139.0 +/- 45.6, p less than 0.05) and one enterocutaneous fistula was closed. White blood cell counts, hemoglobin and alpha-2-globulin did not significantly improve during treatment. Cyclosporin A could be indicated when steroids, sulfasalazine or azathioprine are not effective or not tolerated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651204     DOI: 10.1007/bf02774864

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  13 in total

1.  High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients.

Authors:  G Klintmalm; J Säwe
Journal:  Lancet       Date:  1984-03-31       Impact factor: 79.321

2.  Cyclosporin for Crohn's disease.

Authors:  M C Allison; R E Pounder
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

3.  Cyclosporin in ulcerative colitis.

Authors:  S Gupta; A Keshavarzian; H J Hodgson
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

4.  [Cyclosporin A in acute Crohn disease: initial findings].

Authors:  U A Marbet; K Gyr; G A Stalder
Journal:  Schweiz Med Wochenschr       Date:  1986-07-19

5.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

6.  Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.

Authors:  A A Drosos; F N Skopouli; J S Costopoulos; C S Papadimitriou; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

7.  Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.

Authors:  A W van Rijthoven; B A Dijkmans; H S Goei The; J Hermans; Z L Montnor-Beckers; P C Jacobs; A Cats
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

8.  Treatment of intraocular inflammatory disease with cyclosporin A.

Authors:  R B Nussenblatt; A G Palestine; A H Rook; I Scher; W B Wacker; I Gery
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

9.  [Crohn disease: initial experiences with cyclosporin A in an adolescent girl].

Authors:  G Dannecker; H Malchow; K H Niessen; M B Ranke
Journal:  Dtsch Med Wochenschr       Date:  1985-03-01       Impact factor: 0.628

10.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).

Authors:  W R Best; J M Becktel; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

View more
  3 in total

Review 1.  Cyclosporin for Crohn's disease?

Authors:  M Guslandi; A Tittobello
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Efficacy of cyclosporine in treatment of fistula of Crohn's disease.

Authors:  D H Present; S Lichtiger
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

3.  Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.

Authors:  W J Sandborn; R H Wiesner; W J Tremaine; N F Larusso
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.